PMC:7253482 / 1856-2307
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
67 | 325-330 | Gene | denotes | spike | Gene:43740568 |
76 | 12-22 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
77 | 156-162 | Species | denotes | humans | Tax:9606 |
79 | 37-46 | Disease | denotes | mortality | MESH:D003643 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T10 | 335-343 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T10 | 12-20 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T11 | 12-16 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T10 | 156-162 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T11 | 312-317 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focus |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T10 | 335-343 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 265-274 | http://purl.obolibrary.org/obo/IDO_0000528 | denotes | pathogens |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T282 | 0-8 | RB | denotes | recently |
T283 | 9-11 | IN | denotes | of |
T284 | 12-23 | NN | denotes | SARS-CoV-24 |
T285 | 25-30 | VBN | denotes | Given |
T286 | 31-36 | PRP-DOLLAR- | denotes | their |
T287 | 37-46 | NN | denotes | mortality |
T288 | 47-52 | NNS | denotes | rates |
T289 | 52-53 | -COMMA- | denotes | , |
T290 | 54-57 | DT | denotes | the |
T291 | 58-65 | JJ | denotes | current |
T292 | 66-70 | NN | denotes | lack |
T293 | 71-73 | IN | denotes | of |
T294 | 74-82 | VBN | denotes | targeted |
T295 | 83-93 | NNS | denotes | treatments |
T296 | 94-97 | CC | denotes | and |
T297 | 98-106 | JJ | denotes | licensed |
T298 | 107-115 | NNS | denotes | vaccines |
T299 | 115-116 | -COMMA- | denotes | , |
T300 | 117-120 | CC | denotes | and |
T301 | 121-126 | PRP-DOLLAR- | denotes | their |
T302 | 127-135 | NN | denotes | capacity |
T303 | 136-138 | TO | denotes | to |
T304 | 139-147 | VB | denotes | transmit |
T305 | 148-155 | IN | denotes | between |
T306 | 156-162 | NNS | denotes | humans |
T307 | 163-166 | CC | denotes | and |
T308 | 167-173 | IN | denotes | across |
T309 | 174-181 | NNS | denotes | species |
T310 | 182-193 | NN | denotes | barriers5,6 |
T311 | 193-194 | -COMMA- | denotes | , |
T312 | 195-200 | EX | denotes | there |
T313 | 201-203 | VBZ | denotes | is |
T314 | 204-206 | DT | denotes | an |
T315 | 207-213 | JJ | denotes | urgent |
T316 | 214-218 | NN | denotes | need |
T317 | 219-222 | IN | denotes | for |
T318 | 223-232 | JJ | denotes | effective |
T319 | 233-248 | NNS | denotes | countermeasures |
T320 | 249-251 | TO | denotes | to |
T321 | 252-258 | VB | denotes | combat |
T322 | 259-264 | DT | denotes | these |
T323 | 265-274 | NNS | denotes | pathogens |
T324 | 276-283 | VBG | denotes | Ongoing |
T325 | 284-291 | NN | denotes | vaccine |
T326 | 292-303 | NN | denotes | development |
T327 | 304-311 | NNS | denotes | efforts |
T328 | 312-317 | NN | denotes | focus |
T329 | 318-320 | IN | denotes | on |
T330 | 321-324 | DT | denotes | the |
T331 | 325-330 | NN | denotes | spike |
T332 | 331-332 | -LRB- | denotes | ( |
T333 | 332-333 | NN | denotes | S |
T334 | 333-334 | -RRB- | denotes | ) |
T335 | 335-343 | NNS | denotes | proteins |
T336 | 344-348 | WDT | denotes | that |
T337 | 349-357 | VBP | denotes | protrude |
T338 | 358-362 | IN | denotes | from |
T339 | 363-366 | DT | denotes | the |
T340 | 367-372 | JJ | denotes | viral |
T341 | 373-381 | NN | denotes | envelope |
T342 | 382-385 | CC | denotes | and |
T343 | 386-396 | VB | denotes | constitute |
T344 | 397-400 | DT | denotes | the |
T345 | 401-405 | JJ | denotes | main |
T346 | 406-412 | NN | denotes | target |
T347 | 413-415 | IN | denotes | of |
T348 | 416-428 | VBG | denotes | neutralizing |
T349 | 429-442 | NN | denotes | antibodies7,8 |
T350 | 444-449 | DT | denotes | These |
R277 | T283 | T282 | arg1Of | of,recently |
R279 | T284 | T283 | arg2Of | SARS-CoV-24,of |
R280 | T313 | T285 | arg1Of | is,Given |
R281 | T300 | T285 | arg2Of | and,Given |
R282 | T288 | T286 | arg1Of | rates,their |
R283 | T288 | T287 | arg1Of | rates,mortality |
R284 | T288 | T289 | arg1Of | rates,"," |
R285 | T292 | T289 | arg2Of | lack,"," |
R286 | T292 | T290 | arg1Of | lack,the |
R287 | T292 | T291 | arg1Of | lack,current |
R288 | T292 | T293 | arg1Of | lack,of |
R289 | T296 | T293 | arg2Of | and,of |
R290 | T295 | T294 | arg2Of | treatments,targeted |
R291 | T295 | T296 | arg1Of | treatments,and |
R292 | T298 | T296 | arg2Of | vaccines,and |
R293 | T298 | T297 | arg1Of | vaccines,licensed |
R294 | T300 | T299 | arg1Of | and,"," |
R295 | T289 | T300 | arg1Of | ",",and |
R296 | T302 | T300 | arg2Of | capacity,and |
R297 | T302 | T301 | arg1Of | capacity,their |
R298 | T304 | T303 | arg1Of | transmit,to |
R299 | T302 | T303 | modOf | capacity,to |
R300 | T304 | T305 | arg1Of | transmit,between |
R301 | T306 | T305 | arg2Of | humans,between |
R302 | T285 | T307 | arg1Of | Given,and |
R303 | T308 | T307 | arg2Of | across,and |
R304 | T313 | T308 | arg1Of | is,across |
R305 | T310 | T308 | arg2Of | "barriers5,6",across |
R306 | T310 | T309 | arg1Of | "barriers5,6",species |
R307 | T313 | T311 | arg1Of | is,"," |
R308 | T312 | T313 | arg1Of | there,is |
R309 | T316 | T313 | arg2Of | need,is |
R310 | T316 | T314 | arg1Of | need,an |
R311 | T316 | T315 | arg1Of | need,urgent |
R312 | T316 | T317 | arg1Of | need,for |
R313 | T319 | T317 | arg2Of | countermeasures,for |
R314 | T321 | T317 | arg3Of | combat,for |
R315 | T319 | T318 | arg1Of | countermeasures,effective |
R316 | T321 | T320 | arg1Of | combat,to |
R317 | T319 | T321 | arg1Of | countermeasures,combat |
R318 | T323 | T321 | arg2Of | pathogens,combat |
R319 | T323 | T322 | arg1Of | pathogens,these |
R320 | T328 | T324 | arg1Of | focus,Ongoing |
R321 | T328 | T325 | arg1Of | focus,vaccine |
R322 | T328 | T326 | arg1Of | focus,development |
R323 | T328 | T327 | arg1Of | focus,efforts |
R324 | T328 | T329 | arg1Of | focus,on |
R325 | T335 | T329 | arg2Of | proteins,on |
R326 | T335 | T330 | arg1Of | proteins,the |
R327 | T335 | T331 | arg1Of | proteins,spike |
R328 | T335 | T332 | arg1Of | proteins,( |
R329 | T333 | T332 | arg2Of | S,( |
R330 | T334 | T332 | arg3Of | ),( |
R331 | T335 | T336 | arg1Of | proteins,that |
R332 | T335 | T337 | arg1Of | proteins,protrude |
R333 | T337 | T338 | arg1Of | protrude,from |
R334 | T341 | T338 | arg2Of | envelope,from |
R335 | T341 | T339 | arg1Of | envelope,the |
R336 | T341 | T340 | arg1Of | envelope,viral |
R337 | T337 | T342 | arg1Of | protrude,and |
R338 | T343 | T342 | arg2Of | constitute,and |
R339 | T335 | T343 | arg1Of | proteins,constitute |
R340 | T346 | T343 | arg2Of | target,constitute |
R341 | T346 | T344 | arg1Of | target,the |
R342 | T346 | T345 | arg1Of | target,main |
R343 | T346 | T347 | arg1Of | target,of |
R344 | T348 | T347 | arg2Of | neutralizing,of |
R345 | T349 | T348 | arg2Of | "antibodies7,8",neutralizing |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T10 | 335-343 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T10 | 335-343 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T17 | 12-20 | Species | denotes | SARS-CoV | NCBItxid:694009 |
T18 | 12-16 | Species | denotes | SARS | NCBItxid:694009 |
T19 | 156-162 | Species | denotes | humans | NCBItxid:9605 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 25-275 | Sentence | denotes | Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. |
T15 | 276-443 | Sentence | denotes | Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8. |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T10 | 12-20 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T11 | 12-16 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
76 | 12-22 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
79 | 37-46 | Disease | denotes | mortality | MESH:D003643 |
77 | 156-162 | Species | denotes | humans | Tax:9606 |
67 | 325-330 | Gene | denotes | spike | Gene:43740568 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T714 | 331-343 | Protein | denotes | (S) proteins | https://www.uniprot.org/uniprot/Q9UIP0|https://www.uniprot.org/uniprot/Q9UIN9|https://www.uniprot.org/uniprot/Q9UIN8|https://www.uniprot.org/uniprot/Q9UIN7|https://www.uniprot.org/uniprot/Q9UIN6|https://www.uniprot.org/uniprot/Q9UBH8|https://www.uniprot.org/uniprot/Q9NRH8|https://www.uniprot.org/uniprot/Q9NRH7|https://www.uniprot.org/uniprot/Q9NRH6|https://www.uniprot.org/uniprot/Q9NRH5|https://www.uniprot.org/uniprot/Q9NRH4|https://www.uniprot.org/uniprot/Q9NPG5|https://www.uniprot.org/uniprot/Q9NPE0|https://www.uniprot.org/uniprot/Q9NP52|https://www.uniprot.org/uniprot/Q95IF9|https://www.uniprot.org/uniprot/Q8N5P3|https://www.uniprot.org/uniprot/Q8IZU6|https://www.uniprot.org/uniprot/Q8IZU5|https://www.uniprot.org/uniprot/Q8IZU4|https://www.uniprot.org/uniprot/Q86Z04|https://www.uniprot.org/uniprot/Q7YR44|https://www.uniprot.org/uniprot/Q7LA71|https://www.uniprot.org/uniprot/Q7LA70|https://www.uniprot.org/uniprot/Q5STD2|https://www.uniprot.org/uniprot/Q5SQ85|https://www.uniprot.org/uniprot/Q1XI16|https://www.uniprot.org/uniprot/Q1XI12|https://www.uniprot.org/uniprot/Q15517|https://www.uniprot.org/uniprot/O43509|https://www.uniprot.org/uniprot/O19084|https://www.uniprot.org/uniprot/B0UYZ7|https://www.uniprot.org/uniprot/B0S7V2|https://www.uniprot.org/uniprot/A5A6L9 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 25-275 | Sentence | denotes | Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. |
T15 | 276-443 | Sentence | denotes | Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8. |